Clinical Trial Update: Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study evaluating obatoclax mesylate in combination with topotecan hydrochloride for relapsed or refr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• Obatoclax Mesylate (obatoclax mesylate)
• Topotecan hydrochloride (topotecan hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-07-22